Free Trial

Editas Medicine (EDIT) Competitors

Editas Medicine logo
$2.44 -0.07 (-2.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.46 +0.02 (+1.02%)
As of 08/1/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EDIT vs. BEAM, CRSP, NTLA, SANA, AVDL, ARDX, ELVN, DYN, IOVA, and GPCR

Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Sana Biotechnology (SANA), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Iovance Biotherapeutics (IOVA), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

Editas Medicine vs. Its Competitors

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Editas Medicine has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$32.31M6.32-$237.09M-$3.04-0.80
Beam Therapeutics$63.52M29.81-$376.74M-$4.61-4.08

In the previous week, Beam Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.74 beat Editas Medicine's score of -0.20 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Editas Medicine
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beam Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 2.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Editas Medicine presently has a consensus target price of $4.70, indicating a potential upside of 92.62%. Beam Therapeutics has a consensus target price of $48.75, indicating a potential upside of 158.90%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine
2 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.31
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07

Editas Medicine has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.

Beam Therapeutics has a net margin of -609.24% compared to Editas Medicine's net margin of -701.06%. Beam Therapeutics' return on equity of -44.24% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Editas Medicine-701.06% -139.24% -63.87%
Beam Therapeutics -609.24%-44.24%-30.97%

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDIT vs. The Competition

MetricEditas MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$210.12M$3.00B$5.48B$9.51B
Dividend YieldN/A2.43%4.73%4.09%
P/E Ratio-0.8017.6228.6723.80
Price / Sales6.32179.18373.9066.58
Price / CashN/A41.9535.4557.96
Price / Book1.508.508.275.55
Net Income-$237.09M-$55.06M$3.24B$259.03M
7 Day Performance-22.54%-3.98%-3.69%-4.59%
1 Month Performance-4.69%9.59%4.33%4.46%
1 Year Performance-51.20%6.72%25.95%18.03%

Editas Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDIT
Editas Medicine
3.9706 of 5 stars
$2.44
-2.8%
$4.70
+92.6%
-52.5%$210.12M$32.31M-0.80230News Coverage
Upcoming Earnings
BEAM
Beam Therapeutics
2.6099 of 5 stars
$21.54
+2.4%
$48.75
+126.3%
-37.9%$2.17B$63.52M-4.67510Upcoming Earnings
Insider Trade
Gap Down
CRSP
CRISPR Therapeutics
2.7909 of 5 stars
$65.93
+0.9%
$71.31
+8.2%
+2.3%$5.69B$35M-14.59460Upcoming Earnings
Analyst Revision
Gap Down
High Trading Volume
NTLA
Intellia Therapeutics
4.501 of 5 stars
$13.49
+6.8%
$33.37
+147.4%
-54.3%$1.40B$45.57M-2.58600News Coverage
Upcoming Earnings
Gap Down
SANA
Sana Biotechnology
3.3036 of 5 stars
$4.87
+9.7%
$9.17
+88.2%
-27.1%$1.10BN/A-5.53380News Coverage
Upcoming Earnings
Gap Down
AVDL
Avadel Pharmaceuticals
2.6715 of 5 stars
$11.23
+2.3%
$18.33
+63.3%
-32.9%$1.09B$169.12M-41.5970News Coverage
Positive News
Upcoming Earnings
ARDX
Ardelyx
4.0654 of 5 stars
$4.43
+0.2%
$10.89
+145.8%
-21.3%$1.06B$361.71M-20.1490News Coverage
Upcoming Earnings
ELVN
Enliven Therapeutics
2.469 of 5 stars
$21.56
-1.4%
$41.20
+91.1%
-24.2%$1.06BN/A-11.2350
DYN
Dyne Therapeutics
3.5813 of 5 stars
$9.21
+0.4%
$40.63
+341.1%
-76.1%$1.05BN/A-2.57100Trending News
Earnings Report
Analyst Forecast
Analyst Revision
IOVA
Iovance Biotherapeutics
4.4649 of 5 stars
$3.13
+25.7%
$12.22
+290.5%
-67.2%$1.05B$212.68M-2.52500Upcoming Earnings
Gap Down
High Trading Volume
GPCR
Structure Therapeutics
2.0602 of 5 stars
$18.19
+0.3%
$76.17
+318.7%
-51.7%$1.04BN/A-20.91136News Coverage
Upcoming Earnings
Gap Up

Related Companies and Tools


This page (NASDAQ:EDIT) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners